You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu


Modus Therapeutics partners with Imperial College London on malaria drug

Swedish biotech company Modus Therapeutics has announced a new collaboration with Imperial College London to research the effects of its drug sevuparin in patients with severe malaria.